Industry

FDA clears AI-powered screening software for diabetic retinopathy

Healio Optometry1d ago1 min read

Editor’s note: This is a developing news story. Please check back soon for updates.The FDA granted 510(k) clearance for iPredict-DR, an AI-powered screening software designed to detect more than mild diabetic retinopathy in adults with diabetes, according to a press release from iHealthScreen.The clearance was supported by data from a clinical validation trial that looked at “diagnostic performance, safety and usability.” The software uses AI to examine color retinal fundus images taken with an iCare DRSplus camera, which is designed to be operable by minimally skilled health care workers.

Read full article on Healio Optometry

AI Summary

Quick Take

The FDA has granted 510(k) clearance to iHealthScreen’s iPredict-DR, an AI-based screening tool designed to identify more-than-mild diabetic retinopathy (mtmDR) in adults. The system integrates with the iCare DRSplus fundus camera, allowing non-specialized healthcare staff to perform screenings and receive automated diagnostic results.

Why It Matters

This clearance adds another player to the growing field of autonomous AI screening, addressing the critical gap in diabetic retinopathy (DR) screening rates among the millions of adults with diabetes. By enabling "minimally skilled" workers to operate the system, it facilitates the movement of DR screening into primary care and community settings, potentially increasing early detection and reducing the burden on overstretched specialty clinics. It also signals the continued maturation of AI as a standard-of-care tool for population health management in eye care.

Key Details

The software is specifically indicated for the detection of more-than-mild diabetic retinopathy (mtmDR) in adult patients with diabetes.
It utilizes color retinal fundus images captured via the iCare DRSplus camera system.
The FDA clearance was supported by a clinical validation trial evaluating diagnostic performance, safety, and usability.
The system is designed for use by healthcare workers who do not have specialized ophthalmic training, lowering the barrier for implementation in non-traditional settings.

Practice Implications

Clinicians should prepare for a potential shift in the referral pipeline as autonomous AI tools become more prevalent in primary care settings. While these tools increase screening accessibility, optometrists and ophthalmologists will remain essential for confirmatory diagnosis and management of the increased volume of patients identified with referable disease.

Who's Affected

OptometristsOphthalmologistsPrimary Care PhysiciansPractice OwnersDiabetic Educators

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.